(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 9.35% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 53.04%.
Maxcyte's revenue in 2025 is $37,676,000.On average, 2 Wall Street analysts forecast MXCT's revenue for 2025 to be $4,380,323,518, with the lowest MXCT revenue forecast at $4,305,900,546, and the highest MXCT revenue forecast at $4,454,746,491.
In 2026, MXCT is forecast to generate $5,395,665,499 in revenue, with the lowest revenue forecast at $5,315,926,600 and the highest revenue forecast at $5,475,404,398.